Immunogenicity and bactericidal activity in mice of an outer membrane protein vesicle vaccine against Neisseria meningitidis serogroup A disease (Q43683511)

From Wikidata

Jump to navigation Jump to search

scientific article published in June 2004

Language	Label	Description	Also known as
English	Immunogenicity and bactericidal activity in mice of an outer membrane protein vesicle vaccine against Neisseria meningitidis serogroup A disease	scientific article published in June 2004

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Immunogenicity and bactericidal activity in mice of an outer membrane protein vesicle vaccine against Neisseria meningitidis serogroup A disease (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Neisseria meningitidis

1 reference

based on heuristic

inferred from title

membrane protein

1 reference

based on heuristic

inferred from title

Gunnstein Norheim

1

object named as

Gunnstein Norheim

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Ernst Arne Høiby

2

object named as

E Arne Høiby

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Dominique A Caugant

3

object named as

Dominique A Caugant

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Einar Rosenqvist

7

object named as

Einar Rosenqvist

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Elisabeth Fritzsønn

6

object named as

Elisabeth Fritzsønn

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

5

object named as

Torill Tangen

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

author name string

Ellen Namork

4

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

language of work or name

0 references

publication date

1 June 2004

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

22

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

17-18

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

2171-2180

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Epidemic spread and antigenic variability of Neisseria meningitidis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.047

7 January 2021

Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.047

7 January 2021

Clonal expansion of sequence type (ST-)5 and emergence of ST-7 in serogroup A meningococci, Africa.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.047

7 January 2021

Fit genotypes and escape variants of subgroup III Neisseria meningitidis during three pandemics of epidemic meningitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.047

7 January 2021

The porA gene in serogroup A meningococci: evolutionary stability and mechanism of genetic variation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.047

7 January 2021

Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.047

7 January 2021

Human immunity to the meningococcus. I. The role of humoral antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.047

7 January 2021

A rebuttal: epidemic and endemic meningococcal meningitis in sub-Saharan Africa can be prevented now by routine immunization with group A meningococcal capsular polysaccharide vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.047

7 January 2021

Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.047

7 January 2021

A trial of a group A plus group C meningococcal polysaccharide-protein conjugate vaccine in African infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.047

7 January 2021

Conjugate meningococcal serogroup A and C vaccine: reactogenicity and immunogenicity in United Kingdom infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.047

7 January 2021

Safety and immunogenicity of three doses of a Neisseria meningitidis A + C diphtheria conjugate vaccine in infants from Niger

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.047

7 January 2021

Immunogenicity and immunological priming of the serogroup a portion of a bivalent meningococcal A/C conjugate vaccine in 2-year-old children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.047

7 January 2021

Disparity in functional activity between serum anticapsular antibodies induced in adults by immunization with an investigational group A and C Neisseria meningitidis-diphtheria toxoid conjugate vaccine and by a polysaccharide vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.047

7 January 2021

Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide-protein conjugate vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.047

7 January 2021

Meningococcal serogroup a avidity indices as a surrogate marker of priming for the induction of immunologic memory after vaccination with a meningococcal A/C conjugate vaccine in infants in the United Kingdom.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.047

7 January 2021

Meningococcal conjugate vaccine for Africa: a model for development of new vaccines for the poorest countries

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.047

7 January 2021

Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.047

7 January 2021

Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.047

7 January 2021

Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.047

7 January 2021

Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.047

7 January 2021

Serotyping and subtyping of Neisseria meningitidis isolates by co-agglutination, dot-blotting and ELISA

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.047

7 January 2021

Immunoblot analysis of sera from patients and vaccinees

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.047

7 January 2021

Measurements of lipopolysaccharide (endotoxin) in meningococcal protein and polysaccharide preparations for vaccine usage

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.047

7 January 2021

Determination of antibody responses to meningococcal antigens by ELISA

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.047

7 January 2021

A comparison of the variable antigens expressed by clone IV-1 and subgroup III of Neisseria meningitidis serogroup A

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.047

7 January 2021

Sequence variation in the porA gene of a clone of Neisseria meningitidis during epidemic spread

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.047

7 January 2021

Allelic polymorphism and site-specific recombination in the opc locus of Neisseria meningitidis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.047

7 January 2021

Variable expression of the Opc outer membrane protein in Neisseria meningitidis is caused by size variation of a promoter containing poly-cytidine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.047

7 January 2021

Variation in class 5 protein expression by serogroup A meningococci during a meningitis epidemic.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.047

7 January 2021

Genetic analysis of conservation and variation of lipooligosaccharide expression in two L8-immunotype strains of Neisseria meningitidis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.047

7 January 2021

Development of natural immunity to Neisseria meningitidis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.047

7 January 2021

Persistence of antibodies to meningococcal IgA1 protease versus decay of antibodies to group A polysaccharide and Opc protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.047

7 January 2021

Functional activity of anti-Neisserial surface protein A monoclonal antibodies against strains of Neisseria meningitidis serogroup B.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.047

7 January 2021

PorB3 outer membrane protein on Neisseria meningitidis is poorly accessible for antibody binding on live bacteria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.047

7 January 2021

Immunization with the recombinant PorB outer membrane protein induces a bactericidal immune response against Neisseria meningitidis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.047

7 January 2021

Multiple mechanisms of phase variation of PorA in Neisseria meningitidis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.047

7 January 2021

The 5C protein of Neisseria meningitidis is highly immunogenic in humans and induces bactericidal antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.047

7 January 2021

Lipo-oligosaccharide immunotyping of Neisseria meningitidis by a whole-cell ELISA with monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.047

7 January 2021

Importance of complement source in bactericidal activity of human antibody and murine monoclonal antibody to meningococcal group B polysaccharide.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.047

7 January 2021

Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.047

7 January 2021

based on heuristic

inferred from DOI database lookup

Functional activities and epitope specificity of human and murine antibodies against the class 4 outer membrane protein (Rmp) of Neisseria meningitidis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.047

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of recombinant transferrin-binding protein B variants from Neisseria meningitidis for their ability to induce cross-reactive and bactericidal antibodies against a genetically diverse collection of serogroup B strains

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.047

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2003.11.047

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43683511&oldid=2102485470"